

過去5年間(2014～2018年) 血液内科 海外論文(Original Article)

2018年

Mateos MV, Dimopoulos MA, Cavo M, **Suzuki K**, Jakubowiak A, et al.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
N Engl J Med. 2018;378(6):518-528.

Miyazaki K, Suzuki K.

Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Clin Lymphoma Myeloma Leuk. 2018;18(4):293-296.

Iyoda T, Yamasaki S, **Abe Y, Suzuki K**, et al.
Amelioration of NK cell function driven by $\alpha 24+$ invariant NKT cell activation in multiple myeloma.
Clin Immunol. 2018 Feb;187:76-84.

Tan D, Lee JH, Chen W, **Suzuki K**, et al. Asian Myeloma Network.
Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop.
Leuk Lymphoma. 2018 Feb 2:1-13.

Suzuki K, Dimopoulos MA, Takezako N, et al.

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
Blood Cancer J. 2018;8(4):41.

Shingaki S, **Tsukada N**, Ikeda M, **Suzuki K**.

Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients.
Transplant Proc. 2018 Jan - Feb;50(1):241-245.

Ri M, **Suzuki K**, Iida S, et al.

A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma.
Intern Med. 2018;57(7):939-946.

Kirito K, **Suzuki K**, Miyamura K, et al.

Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Int J Hematol. 2018;107(2):173-184.

Iida S, Ichinohe T, Shinagawa A, **Suzuki K**, et al.

Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
Int J Hematol. 2018;107(4):460-467.

Kawamura K, **Tsukada N**, Kanda Y, **Ishida T, Suzuki K**, et al.

The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: a Study From the Japanese Society of Myeloma.
Biol Blood Marrow Transplant. 2018 Mar 16.

Tan D, **Suzuki K**, et al. Asian Myeloma Network
Recent advances in the management of multiple myeloma: clinical impact based on
resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international
myeloma workshop.

Leuk Lymphoma. 2018 Oct;59(10):2305-2317.

Matsue K, Kumagai K, **Suzuki K**, et al.
Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in
Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.

Int J Hematol. 2018 Nov;108(5):524-534.

Miyazaki K, Suzuki K.

Poor mobilizer and its countermeasures.

Transfus Apher Sci. 2018 Oct;57(5):623-627.

Dimopoulos MA, Dytfeld D, **Suzuki K**, et al.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med. 2018 Nov 8;379(19):1811-1822.

2017年

Suzuki K, et al.

Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients
with relapsed/refractory multiple myeloma.

Int J Hematol. 2017;105:445-452.

Suzuki K, et al.

Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A
phase 1 study in Japan.

Cancer Sci. 2017;108:461-468.

Futami M, **Sato K, Miyazaki K, Suzuki K**, Nakamura T, Tojo A.

Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple
Myeloma.

Mol Ther Oncolytics. 2017 22;6:57-68.

Meshitsuka S, Shingaki S, Suzuki K, et al.

Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Int J Hematol. 2017;105:295-308.

Ogura M, Ishizawa K, **Suzuki K**, et al.

Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin
lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.

Int J Hematol. 2017;105:470-477.

Ri M, Matsue K, **Suzuki K**, et al.

Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for
autologous transplantation in Japanese patients with multiple myeloma.

Int J Hematol. 2017;106(4):562-572.

Iida S, **Suzuki K**, Kusumoto S, Abe Y, et al.

Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a
multicenter, phase 1, dose-escalation study.

Int J Hematol. 2017;106(4):541-551.

2016年

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, **Suzuki K**, et al.

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med. 2016;375(14):1319-1331.

Miyazaki K, Suzuki K.

Capillary electrophoresis/immun subtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis.
Amyloid. 2016;23:221-224.

Ichinohe T, Kuroda Y, **Suzuki K**, et al.

A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial.
Exp Hematol Oncol 2016.5:11.

Mu S, Kuroda Y, **Suzuki K**, et al.

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Eur J Clin Pharmacol. 2016;72:153-161.

Kitamura K, **Miyazaki K, Suzuki K**, et al.

Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood.
Int J Hematol. 2016;103:53-62.

T Watanabe, **K Suzuki**, S Iida, et al.

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Br J Haematol. 2016;172(5):745-56.

C Shimazaki, S Fuchida, **K Suzuki**, et al.

Phase 1 Study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL Amyloidosis.
Int J Hematol 103:79-85,2016

Suzuki K, et al.

Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study.
Cancer Sci. 2016;107(5):653-8.

Shimazaki C, Fuchida S, **Suzuki K**, et al.

Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.
Int J Hematol. 2016;103:79-85.

Tsukada N, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Yoshiki Y, Abe Y, Suzuki K.

High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.
Int J Hematol. 2016;103(3):299.

Suzuki K, Shinagawa A, Uchida T, et al.

Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study.
Cancer Sci. 2016;107:653-658.

2015年

Suzuki K, Abe Y, et al.

Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.

Int J Hematol 2015;101(3):286-94

Miyazaki K, Suzuki K.

Clinical and laboratory significance of CD56 (a neural cell adhesion molecule) positivity in multiple myeloma and AL amyloidosis.

Int J Myel 5(3): 30–35, 2015

Miyazaki K, Kawai S, **Suzuki K**.

Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry.

Int J Hematol 102:289-295,2015.

2014年

Miyazaki K, Suzuki K

Unusual intracytoplasmic crystalline inclusions in chronic myelomonocytic leukemia with double minute chromosomes and MYC amplification: A rare case.

Acta Hematol 132:68-72,2014

Ozaki S, Harada T, Saitou T, **Suzuki K**, et al

Survival of multiple myeloma patients aged 65-70 years in the Era of novel agents and autologous stem cell transplantation.

Acta Hematol. 132:211-219,2014

Kim K, Lee H, Kim JS, **Suzuki K**, et al

Clinical profiles of multiple myeloma in Asia-An Asian myeloma network study.

Am J Hematol 89:751-756, 2014

～2013年

K Suzuki

Current therapeutic strategy for Multiple myeloma.

Jpn J Clin Oncol 43:116, 2013

Ogawa Y, **Suzuki K**, Hotta T, et al

Phase 1/2 study of bortezomib-melphalan- Prednisolone for previously untreated Japanese patients with multiple myeloma.

Cancer Science 104:912-919, 2013

Nakagawa Y, Suzuki K, Masaoka T, et al

Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia.

J Infect Chemother 19:103-111, 2013.

S Yoshizawa, JH Ohyashiki, M Ohyashiki, T Umezumi, **K Suzuki**, et al.

Down regulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders.

Blood Cancer Journal 2:e53, 2012

K Suzuki

Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.

Clin Exp Nephrol. 16:659-671, 2012

Y Nakagawa, K Suzuki, A Urabe et al.

Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study.

J Infect Chemother 17:58-67, 2011

Nicol AJ, H Tokuyama, **K Suzuki**, M Nieda, et al.

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.

Br J Cancer 105:778, 2011